Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with ...

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast ...

The FDA has granted clearance to an investigational new drug application for CLD-201 for solid tumor treatment, based on ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia ...